In this article, we will discuss about Everolimus (Dosage Overview). So, let’s get started.
Everolimus (AFINITOR) is a kinase inhibitor indicated for the treatment of patients with:
• Advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
• Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of AFINITOR is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.
• 10 mg once daily with or without food.
• For patients with Child-Pugh class B hepatic impairment, reduce the
AFINITOR dose to 5 mg once daily.
• If moderate inhibitors of CYP3A4 and/or P-glycoprotein (PgP) are required, reduce the AFINITOR dose to 2.5 mg once daily; if tolerated, consider increasing to 5 mg once daily.
• If strong inducers of CYP3A4 are required, increase AFINITOR dose in 5
mg increments to a maximum of 20 mg once daily.
• Initial dose based on body surface area with subsequent titration to attain through concentrations of 5-10 ng/mL.
• If moderate inhibitors of CYP3A4 and/or PgP are required, reduce the
AFINITOR dose by approximately 50%. Subsequent dosing should be
based on therapeutic drug monitoring (TDM).
• If strong inducers of CYP3A4 are required, double the AFINITOR dose.
Subsequent dosing should be based on TDM.